Compare iShares MSCI Germany (DAX) (EWG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Incyte Corporation — how do they compare? iShares MSCI Germany (DAX) trades at $40.87 (market cap $1.42B), while Incyte Corporation trades at $113.2 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 16.1× iShares MSCI Germany (DAX)'s market cap, and Incyte Corporation is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 56 Days and Incyte Corporation for 33 Days on average.
| EWG | INCY | |
|---|---|---|
Market Cap | $1.42B | $22.85B |
Volume | 1,110,573 | 1,927,029 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $129.93 |
52-Week Low | $38.08 | $83.80 |
Typical Hold Time | 56 Days | 33 Days |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $40.91, down 1.4% with a bearish technical outlook showing 19 sell signals versus 1 buy. The stock faces resistance at $41 with support at $40. Technical indicators show oversold conditions with RSI at 25.94, but moving averages and oscillators remain bearish. Recent European market sentiment is mixed with ECB rate hikes and energy price concerns affecting regional equities.
Investment outlook remains cautious given the bearish technical signals and macroeconomic pressures from ECB tightening. The stock's proximity to support levels suggests potential for near-term stabilization, but sustained recovery requires improved fundamental performance and easing of European economic concerns.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
